Literature DB >> 8099650

Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction?

P M Ridker1, P R Hebert, V Fuster, C H Hennekens.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8099650     DOI： 10.1016/0140-6736(93)90707-n

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  The TIMI 9b and GUSTO IIb Trials and the "Thrombin Hypothesis"

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 2.  Criteria for drug usage review of thrombolytics in acute myocardial infarction.

Authors:  S McGlynn
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

Review 3.  Aspirin for myocardial infarction. Clinical pharmacokinetic considerations.

Authors:  F Bochner; J V Lloyd
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

4.  Direct Comparison of Aspirin Plus Hirudin, Aspirin Plus Heparin, and Aspirin Alone Among 12,000 Patients with Acute Myocardial Infarction Not Receiving Thrombolysis: Rationale and Design of the First American Study of Infarct Survival (ASIS-1).

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

5.  Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials.

Authors:  R Collins; S MacMahon; M Flather; C Baigent; L Remvig; S Mortensen; P Appleby; J Godwin; S Yusuf; R Peto
Journal:  BMJ       Date:  1996-09-14

6.  Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Fraxiparin Anticoagulant Therapy in Myocardial Infarction Study Amsterdam (FATIMA) Study Group.

Authors:  S A Chamuleau; R J de Winter; M Levi; R Adams; H R Büller; M H Prins; K I Lie; R J Peters
Journal:  Heart       Date:  1998-07       Impact factor: 5.994
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.